Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of phase II and III trials center around neurotransmitter receptors and Aβ mechanisms, while tau and inflammation drugs are more prominent in phase II, often featuring repurposed compounds.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [436]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, drug development landscape for combination therapy is becoming increasingly crowded with both symptomatic and disease-modifying applications.51”
From From combinations to multitarget-directed ligands: A continuum in Alzheimer’s disease polypharmacology (2021) · cites this paper as [51]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The major mechanisms of action center around: 1) neurotransmitter receptors, including AChE, NMDA receptor, 5-hydroxytryptamine receptor, nicotinic α7 receptor, and adrenoceptor; 2) Aβ, including the reduction of Aβ production (such as γ-secretase inhibitors and modulators, BACE1 inhibitors, and α-secretase activators), prevention of Aβ aggregation, and enhancing Aβ clearance (vaccines and ant”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [436]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657 · cited 1×
“The use of CSF biomarkers in research and clinical trials, in addition to clinical criteria is detailed in the revised diagnostic criteria of AD [24, 105], suggesting the use of CSF biomarkers in differentiating between AD and other types of dementia.”
MethodThe Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152 · cited 3×
“The use of CSF biomarkers in research and clinical trials, in addition to clinical criteria is detailed in the revised diagnostic criteria of AD [24, 105], suggesting the use of CSF biomarkers in differentiating between AD and other types of dementia.”
BackgroundMethodNeuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226 · cited 1×
“Similarly, stage-dependent efficacy of anti-inflammatory agents, suggests that these treatments may be useful early in AD [90, 103].”
BackgroundAlzheimer's Disease: Genes, Proteins, and Therapy
Selkoe, D. J. (2001) · Physiological Reviews · doi:10.1152/physrev.2001.81.2.741 · Cited by 6,063
Complement and microglia mediate early synapse loss in Alzheimer mouse models
Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., Merry, K. M., Shi, Q., Rosenthal, A., Barres, B. A., et al. (2016) · Science · doi:10.1126/science.aad8373 · Cited by 3,343
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2013) · Focus · doi:10.1176/appi.focus.11.1.96 · Cited by 2,621
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558 · cited 1×
“Further, new understanding of the multiple roles of microglia and factors that affect their function in the progression of AD [10, 11, 35, 56, 57], has potential to open vastly new therapeutic options and targets.”
Background
Research works printed but not linked: 7
- Lilly Press Release, Update on Phase 3 Clini- cal Trials of Lanabecestat for Alzheimer's Disease. https://investor.lilly.com/node/39051/pdf, Posted June 12, 2018, Accessed February13, 2019.
- Merck Press Release, Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy, https://investors.merck.com/news/press- release-details/2017/Merck-Announces-EPOCH-Study- of-Verubecestat-for-the-Treatment-of-People-with-Mild- to-Moderate-Alzheimers-Disease-to-Stop-for-Lack-of- Efficacy/, Posted February 14, 2017, Accessed February 13, 2019.
- Biogen Press Release, Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of Aducanumab in Alzheimer's Disease, http://investors.biogen.com/news- releases/news-release-details/biogen-and-eisai- discontinue-phase-3-engage-and-emerge-trials, Posted March 21, 2019, Accessed March 29, 2019.
- Biogen Press Release, Eisai and Biogen Announce Posi- tive Topline Results of the Final Analysis for BAN2401 at 18 Months, http://investors.biogen.com/news- releases/news-release-details/eisai-and-biogen- announce-positive-topline-results-final, Posted July 5, 2018, Accessed February 13, 2019.
- Roche Press Release, Roche to discontinue Phase III CREAD 1 and 2 clinical studies of crenezumab in early Alzheimer's disease (AD) -other company programmes in AD continue, https://www.roche.com/media/releases/med-cor-2019- 01-30.htm, Posted January 30, 2019, Accessed March 29, 2019.
- Lilly Press Release, Lilly Announces Top-Line Results of Solanezumab Phase 3 Clinical Trial, https://investor.lilly.com/static-files/9117f89a-0f6a- 4dd8-a73e-97c108cf613d, Posted November 23, 2016, Accessed February 13, 2019.
- Lilly Press Release, Lilly Voluntarily Terminates Phase II Study for LY2886721, a Beta Secretase Inhibitor, Being Investigated as a Treatment for Alzheimer's Disease, https://investor.lilly.com/news-releases/news- release-details/lilly-voluntarily-terminates-phase-ii- study-ly2886721-beta, Posted June 13, 2016, Accessed February 13, 2019.
Cited by
Items 101–130 of 130
Latina, V., Introna, M. D., Malerba, F., Florio, R., Balzamino, B., Natale, G. D., Sciacca, M., Pappalardo, G., Micera, A., Pignataro, A., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02022-y · Cited by 3
“Therefore, the optimization of the administration regimen is of paramount importance in the pipeline of “candi-date” therapeutic antibodies in order to achieve higher clinical benefit, tolerability and safety with consequent amelioration in compliance of affected patients [137– 139].”
Khalaf, H. S., El-Sayed, A. F., & Shamroukh, A. H. (2025) · RSC Advances · doi:10.1039/d5ra07372c · Cited by 4
Brain morphology mediating the effects of common genetic risk variants on Alzheimer’s disease
Breddels, E. M., Snihirova, Y., Pishva, E., Gülöksüz, S., Blokland, G. A. M., Luykx, J. J., Andreassen, O. A., Linden, D. E. J., van der Meer, D., & Initiative, A. D. N. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251328300 · Cited by 3
Borsom, E. M., Conn, K. A., Keefe, C. R., Herman, C., Orsini, G. M., Hirsch, A. H., Avila, M. P., Testo, G., Jaramillo, S. A., Bolyen, E. K., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1538737/v1 · Cited by 3
γ-secretase targeting in Alzheimer's disease
Du, L., Li, G., Wei, Y., & Han, G. (2025) · Journal of Alzheimer s Disease Reports · doi:10.1177/25424823251349529 · Cited by 4
“69 GSIs are usually present as small molecules, and the speci fi c mechanism of action is directly binding to the active or regulatory sites of the γ -secretase complex.”
Bahadur, A., Iqbal, S., Shoaib, M., Zulqarnain, M., Shah, M., Abd‐Rabboh, H. S. M., Perwez, U., Qayyum, M. A., & Zaman, A. (2021) · ChemistrySelect · doi:10.1002/slct.202101634 · Cited by 2
Si, G., & Сафарова, Т. П. (2021) · Psikhiatriya · doi:10.30629/2618-6667-2021-19-2-87-103 · Cited by 2
Peterson, K. A., Leddy, A., & Hornberger, M. (2025) · PLOS Digital Health · doi:10.1371/journal.pdig.0000682 · Cited by 5
Peterson, K. A., Leddy, A., Ellis, F., Meiser‐Stedman, R., & Hornberger, M. (2025) · Neuropsychology Review · doi:10.1007/s11065-025-09688-0 · Cited by 1
A new neuroprotective candidate TJ1 targeting amyloidogenesis in 5xFAD Alzheimer’s disease mice
Deng, J., Huang, L.-F., Bian, Z.-Y., Feng, X.-Y., Qi, R.-Y., Dong, W.-X., Gao, J., & Tang, J. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.112653 · Cited by 1
Estudio teórico de SFRP1 como nueva diana terapéutica para el tratamiento del Alzheimer
Carrasco-Rubio, L., González-Carrion, E., Martínez-del-Río, J., & Martínez-Pasabados, I. (2020) · Dianas · doi:10.37536/dianas.2020.9.1.53
“(Elmaleh et al., 2019).”
BackgroundLv, X., Qiu, J., Jiang, H., & Tan, Y. (2021) · Turkish Journal of Field Crops
Rui, W., Xiao, H., Yi, F., Ma, Z., Xiao, M., Li, S., & Shi, J. (2021) · Research Square · doi:10.21203/rs.3.rs-502155/v1
A comprehensive analysis of APOE genotype effects on human brain structure in the UK BiobankPreprint
Heise, V., Offer, A. R., Whiteley, W. N., Mackay, C. E., Armitage, J., & Parish, S. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.06.19.543571
Brain morphology mediating the effect of genetic risk variants on Alzheimer’s diseasePreprint
Breddels, E. M., Snihirova, Y., Pishva, E., Gülöksüz, S., Blokland, G. A. M., Luykx, J. J., Andreassen, O. A., Linden, D. E. J., van der Meer, D., & Initiative, A. D. N. (2024) · medRxiv · doi:10.1101/2024.01.12.24301205
Nanotechnology Based Therapeutic Approach in Alzheimer's
Samiullah, M., Chauhan, K., Manimekalai, K., Sherief, S. H., Pandya, M. K., Ahmed, S., Bhaskar, R., & Prakash, J. (2024) · Journal for Research in Applied Sciences and Biotechnology · doi:10.55544/jrasb.3.3.24
“When combined with polysaccharides, the nanoparticles not only displayed outstanding stability, hydrophilicity, and biodegradability, but they were also non-toxic when employed on their own[55].”
BackgroundLiu, A. Y. ‐., Mathew, A., Karim, C., Eshak, P., & Chen, K. Y. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.08.005
Bioengineering of Marine Metabolite-Based Nanotheranostics for Effective Alzheimer's Treatment
Govindaswamy, B., Kumarappan, M., & Stephen, K. N. (2024) · Advances in medical technologies and clinical practice book series · doi:10.4018/979-8-3693-5878-8.ch008
Waheed, R., Mostafa, Z., Emad, M., Darwish, S. S., Purgatorio, R., Miniero, D. V., Palma, A. D., Cheng, T., Wang, T., Chen, Y., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118261 · Cited by 1
Dysregulated serum miR-384-5p as a diagnostic biomarker for Alzheimer’s disease
Miao, Y., Zheng, J., Huang, T., Wang, X., & Zhang, R. (2025) · Turkish Journal of Biochemistry · doi:10.1515/tjb-2025-0113
Mild Synthesis of 4-Aryl- 1H -pyrazolo[3,4- b ]pyridines Using Fe 3 O 4 @SP@GBP Nanocomposite
Ziabari, F. B., Gitimehr, N., Nikpassand, M., Mokhtary, M., & Fekri, L. Z. (2025) · Organic Preparations and Procedures International · doi:10.1080/00304948.2025.2579760
Exploration de nouveaux biomarqueurs plasmatiques pour le diagnostic de la maladie d’Alzheimer
Rossi, E. (2021) · theses.fr (ABES) · doi:10.70675/71230be4z1955z4fafzb1b8z8ff71a4edaff
Lam, S. (2021) · theses.fr (ABES) · doi:10.70675/60b353ffz56fcz41a2z9e53zf0d9ac078167 · Cited by 1
Emenheiser, A. M., Gentry, E., Xue, H., Alvarez, P., O’Neill, K. M., Cao, K., & Losert, W. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.28.728474
Secoisolariciresinol diglucoside ameliorates Alzheimer-like lesions by increasing MKP-1
Chen, M., Xie, Q., Yi, F., Ma, J., Lu, S., Ouyang, H., Qin, Y., Yang, S., (21173), W. W., & Liu, Y. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261450557
“8 However, due to the insidious onset of AD, most patients are already in the middle to late stages of the disease by the time they seek medical attention, making it challenging to achieve satisfactory outcomes with single-target drugs directed at either A β or tau.”
Alzheimer’s Disease: Molecular Pathophysiology and Current Therapeutic Management
Shingade, S. S., Mandhare, T. A., Mujumale, J. S., Kashid, P., & Otari, K. V. (2026) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/3523
Salama, A., Mohammed, M. A., & Mohasib, R. M. M. (2026) · Beni-Suef University Journal of Basic and Applied Sciences · doi:10.1186/s43088-026-00768-5
“The challenge of treating AD remains since their primary impact is on mitigating its symptoms rather than slowing down the disease’s advancement [7].”
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“Neurotransmitter receptors and A b -related pathways are the focus of many phase-II and III trials, whilst phase II trials are being conducted for medications that reduce neuroin fl ammation and tau aggregation, including repurposed medicines (170, 171).”
BindingDB Entry 50015539: Histamine H
BindingDB (2023) · UC San Diego · doi:10.7270/q2dr30df
Metadata
- Authors
- Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E.
- Affiliations
- Massachusetts General Hospital (US)
- Indiana University School of Medicine (US)
- University of Southern California (US)
- Harvard University (US)
- AZTherapies (United States) (US)
- Corresponding author
- Elmaleh, David R.
- Venue
- Journal of Alzheimer’s Disease
- Publisher
- SAGE Publications
- Published
- 2019-08-27
- Volume
- 71
- Issue
- 3
- Pages
- 715-732
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC6839593
- OpenAlex
- W2971180542
- Cited by
- 129
- References
- 102
- Citations by year
- 2026: 5 · 2025: 12 · 2024: 22 · 2023: 20 · 2022: 16 · 2021: 29 · 2020: 24 · 2019: 1
- FWCI
- 2.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (acceptedVersion, cc-by)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- PMC
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, disease-modifying drugs
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Cognition, Humans, Middle Aged, Biomarkers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.